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Neuroblastoma accounts for around 15% of childhood cancer deaths. Survival rates are now 
slowly improving, but remain dire with less than 50% overall-survival for high-risk 
neuroblastomas [1]. Scientists and clinicians gathered at the 3rd Neuroblastoma Research 
Symposium in Liverpool on 6th-7th November 2013, organised by The Neuroblastoma 
Society charity, to discuss and share advances in the understanding of neuroblastoma 
biology and in the development of potential new therapies.  
Epigenetic landscape of neuroblastoma 
Driver genetic mutations in neuroblastoma are rare [2], while gene silencing by methylation 
is emerging as an important characteristic of high-risk neuroblastoma development. Jo 
Vandesompele (Ghent University) explained that aberrant DNA methylation patterns may 
contribute to the neuroblastoma phenotype by down-regulating specific genes and 
microRNAs involved in neuroblastoma biology. Most importantly, DNA methylation may be 
used as biomarkers to refine neuroblastoma risk classification, although the independent 
prognostic value of such methylation signatures over already known established risk factors 
remains to be established [3]. Further supporting the notion that epigenetic mechanisms 
contribute to neuroblastoma pathogenesis, Gudrun Schleiermacher (Institute Curie) reported 
that new mutations in tumours at relapse are rare, while histone methyltransferase (HMT) 
activity was often elevated. Histone methylation is also responsible for tumour suppressor 
gene silencing as highlighted by Karim Malik (University of Bristol), who showed an example 
of a gene encoding a pro-apoptotic protein repressed by HMTs. Drugs inhibiting HMTs were 
able to reactivate gene expression and trigger apoptosis, emphasizing the potential of 
epigenetic modulation for neuroblastoma therapies. It is hoped that future work in the 
epigenetics field will identify potential new drug targets. One possibility is EZH2, a 
component of the polycomb repressor complex 2 that interacts directly with MYCN to 
mediate transcriptional repression. A functional characterisation of genes differentially 
methylated between neuroblastoma prognostic sub-groups as well as between MYCN-
amplified and MYCN-non amplified cases will provide further candidates. 
 
The role of MYCN in childhood cancers 
Historically, inhibiting MYC proteins with small molecules has proved difficult due to the 
complex nature of targeting transcription factor protein-protein and protein–DNA interactions. 
Evon Poon (Institute of Cancer Research) presented an elegant study describing how 
MYCN-amplified neuroblastoma cells depend on Aurora kinase A (AURKA) to protect MYCN 
from FBW7 mediated degradation. AURKA inhibitors promote conformational changes within 
the kinase domain of AURKA, blocking MYCN binding and destabilising the oncoprotein [4]. 
Jo Vandesompele introduced another promising avenue, presenting newly identified 
miRNAs that interact with MYCN transcripts.  
Disruption of MYCN activity in MYCN-amplified neuroblastoma cells induces growth arrest, 
differentiation and apoptosis. Marie Arsenian Henriksson’s group (Karolinska Institute) have 
shown that MYCN knockdown or inhibiting the MYCN-MAX interaction using the inhibitor 
10058-F4 induces the formation of lipid vesicles in the cytoplasm of neuroblastoma cells. 
Proteomic analysis revealed that reduction of MYCN leads to a decrease in respiratory chain 
and β-oxidation of fatty acids associated proteins [5]. Targeting MYCN activity with small 
molecule inhibitors requires a comprehensive model of both the mechanisms governing 
MYCN protein stability and the pathways influencing MYCN inhibition.  
MYCC and MYCN are oncogenic drivers in medulloblastoma, a childhood tumour of the 
cerebellum. Steve Clifford (Newcastle University) explained that while MYCC amplification is 
strongly associated with poor prognosis, the significance of MYCN amplification for 
prognosis is dependent on additional factors, such as metastatic status [6]. Over-expression 
of MYC has paradoxical effects on cancer cells: driving proliferation and sensitising cells to 
apoptosis. Current studies targeting MYCN do not address how to inhibit MYCN driven 
proliferation without protecting cells from apoptosis. Future studies must precisely define the 
relevant pathways downstream of MYCN and aim for a comprehensive understanding of 
how developmental differences and additional risk factors influence the aggressiveness of 
MYCN driven malignancies.  
Alongside MYCN, novel targets presented at the meeting included TAK1, Wee1 and PI3 
kinase (Daniel Morgenstern, GOSH), BRD4 (Emma Bell, DKFZ) and p53-MDM2 antagonists 
as inhibitors of MDR-1 (Lindi Chen, Newcastle University). Taken together, these 
presentations had a clear message: Future successful treatment of neuroblastoma depends 
on intelligent design of drug combinations. 
In-vivo neuroblastoma models 
Getting a new drug into clinical trial requires proof-of-response in preclinical animal models. 
Laura Danielson (Institute of Cancer Research) provided an overview of transgenic 
neuroblastoma murine models. The TH-MYCN mouse was the first and is now well-
established [7]. With advances in technology and the identification of further 
genetic/biological aberrations in neuroblastoma, additional transgenics are emerging (e.g. 
ALKF1147L, LIN28B, Caspase-8 deficient, MYCN/NCYM) [8-12]. The utility of the ALK model 
is of particular interest as ALK is a novel therapeutic target in neuroblastoma. Suzanne 
Turner (University of Cambridge) presented an overview of the well-established ALK 
induced mechanisms in Anaplastic Large Cell Lymphoma (ALCL) and an encouraging 
example of how the NPM-ALK transgenic mouse enabled the successful treatment of a 
relapsed ALCL patient with Imatinib [13].  
A major limitation of neuroblastoma murine models has been the lack of distant metastases; 
however both the caspase-8 deficient and MYCN/NCYM models appear to have overcome 
this and may prove highly useful in the future. Louis Chesler’s group (Institute of Cancer 
Research) are establishing a doxycycline-regulatable MYCN-off model that will enable 
greater control and understanding of MYCN during neuroblastoma tumourigenesis and 
oncogenic addiction.  
Anti-GD2 immunotherapy is now routinely used in the clinic. Poster presentations at the 
symposium highlighted the ongoing efforts to enhance the efficacy of GD2 therapy by the 
co-administration of immune adjuvants. Juliet Gray (University of Southampton) discussed 
the importance of immunocompetent murine models, in view of the difficulties of 
recapitulating the immune microenvironment in vitro. The TH-MYCN mouse model was 
found to be the most comparable with neuroblastoma patients with respect to GD2 
expression and the immune environment. More specifically, TH-MYCN+/- mice are preferred 
over TH-MYCN+/+ mice due to longer tumour latency, enabling the development of a more 
mature immune system. The narrow therapeutic window in which to assess immunotherapy 
strategies due to tumour burden has been a major challenge. To overcome this, Gray and 
colleagues use a sub-therapeutic dose of cyclophosphamide (40mg/kg) to control tumour 
burden. The utility of the new generation of transgenic mouse models for studying 
immunotherapy remains to be established.   
Violaine Sée (University of Liverpool) described the development of a metastatic model 
system in the chick embryo in which the behaviour and transport of fluorescently tagged 
neuroblastoma cells within the vascular system could be visualised. Cells with prior 
exposure to hypoxia were more likely to attach to vessel walls and invade local tissue, 
suggesting that hypoxia-activated genes could be therapeutic targets. Metastasis was also 
the focus of posters by Sue Burchill’s group (University of Leeds), who are isolating stem 
cell-like neuroblastoma cells that have disseminated to the bone marrow, and by Rob 
Falconer’s team (University of Bradford), who are developing inhibitors of the enzyme 
responsible for the production of cell-surface polysialic acid to reduce tumour cell 
dissemination [14].  
Facilitated by Louis Chesler, lively discussions focused on the need for models not involving 
MYCN, representing the different subgroups or stages of disease (pre-treatment, minimal 
residual disease, relapse), and whether a “murine models consortium” should be established 
to help facilitate the development of such valuable research models. Further discussions 
touched on other cheaper models, primarily zebrafish, Xenopus frog and fruit fly, each of 
which offer something unique to cancer modelling, particularly for understanding conserved 
pathways affected in neuroblastoma. However novel routes to treatment would continue to 
require in vivo mouse models.  
Differentiating neuroblastoma 
The administration of 13-cis-retinoic acid (RA) induces neuroblastoma differentiation and 
leads to improved survival rates [15]. Gareth Veal (Newcastle University) demonstrated the 
importance of monitoring the ratio of parent drug to metabolite obtained in plasma and of 
subsequent adjustments to the second dosage of RA to achieve the specified therapeutic 
dose [16]. The need to consider carefully drug formulation when administered to children 
was discussed. Andy Stoker (UCL) presented mechanisms for how oxovanadium 
compounds, protein tyrosine phosphatase inhibitors given to patients with diabetes, drive 
neuroblastoma differentiation and senescence in combination with RA [17].  
Approaching neuroblastoma therapy with expertise from developmental biology, Marthe 
Howard (University of Toledo) and Anna Philpott (University of Cambridge) focused on 
Hand2 and ASCL-1, respectively. Both transcription factors are required for the 
differentiation of sympathetic neurons [18] and are implicated in aggressive neuroblastomas. 
The talks reported progress towards a mechanistic understanding of how neuronal 
differentiation occurs normally and hence how this process could be encouraged 
therapeutically in neuroblastoma. Howard showed that the key neuroblastoma genes MYCN, 
ALK and Phox2B are direct targets of Hand2, and that siRNA knockdown of Hand2 in cell 
lines led to a reduction in protein levels of all three. Hence Hand2 emerges with therapeutic 
potential. 
Anna Philpott reported that both the amount of ASCL-1 and its phosphorylation by CDK2, 
control the fate of sympathetic neurons. Dephosphorylation of ASCL-1 leads to cell cycle exit 
and differentiation, both in normal development and in neuroblastoma cells, suggesting a 
mechanism for why CDK inhibitors are effective in neuroblastoma [19]. Through 
mechanisms that are not yet fully understood, RA works synergistically with CDK inhibition 
and potentially ASCL-1 dephosphorylation, with Hand2 knockdown and with oxovanadium 
compounds above. Understanding this synergy could bring significant improvements to 
differentiation therapies that are urgently needed to reduce the risk of relapse.  
Conclusion 
Finding therapeutic synergies through a mechanistic understanding of how drug 
combinations affect neuroblastomas, and developing and testing these in a range of animal 
models, is the most promising route to improve current therapies. Therapeutic synergies will 
bring efficacy but also specificity to tumour cells, crucial for reducing long-term side effects in 
pediatric patients. A mechanistic understanding is essential for identifying the likely key 
pharmacokinetic measures that will allow precise monitoring of drug efficacy and patient 
differences in response. The 4th Neuroblastoma Research Symposium will be held in the 
autumn of 2015 in Newcastle, UK. 
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